Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus PHENYLEPHRINE HYDROCHLORIDE IN 0 9 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus PHENYLEPHRINE HYDROCHLORIDE IN 0 9 SODIUM CHLORIDE.
MAGNESIUM SULFATE vs PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction, increasing peripheral vascular resistance and blood pressure.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion: initial rate 100-180 mcg/min, titrate to effect; maintenance 40-60 mcg/min. Concentrations: 100 mcg/mL (10 mg in 100 mL NS) or 200 mcg/mL (20 mg in 100 mL NS). Administer via central line preferred.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Terminal elimination half-life: 2-3 hours; clinical context: requires repeated dosing or continuous infusion for sustained effect.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Primarily renal (80-90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."